MacroGenics, Inc. (NASDAQ:MGNX) currently has an Average Broker Rating of 1.43. This number is based on the 7 sell-side firms polled by Zacks. The ABR rank within the industry stands at 57. Analysts on a consensus basis are expecting that the stock will reach $30.83 within the year. The ABR is provided by Zacks which simplfies analyst ratings into an integer based number. They use a one to five scale where they translate brokerage firm Buy/Sell/Hold recommendations into an average broker rating. A low number in the 1-2 range typically indicates a Buy, 3 represents a Hold and 4-5 represents a consensus Sell rating.
Investors may be searching high and low for the secret to attaining success in the markets. Knowing when to sell can be just as important as deciding which stocks to buy. Holding on to a loser for too long may leave a sour taste in the mouth. Investors may have unrealistic expectations about a particular name. Knowing when to cut and run can be a gigantic savior for overall portfolio health. Of course if investors end up selling winners too early, they will most likely be leaving too much profit on the table. Finding a good balance and knowing overall market conditions can help with the decision if the time has come. Closely tracking fundamentals and technicals can help give some insight into stock price behavior. Making sure company earnings are in line may also be a wise choice when investing in a recently researched stock.
An evaluation of a stock’s expected performance and/or its risk level as judged by a rating agency such as Standard and Poor’s. A stock rating will usually tell the investor how well a stock’s market value relates to what analysts believe is a fair value for the stock, based on an objective evaluation of the company. The greater the amount by which the fair value exceeds the market value, the more highly recommended a buy the stock is. Conversely, if the market value of the stock exceeds the fair value of the stock, then analysts recommend that the stock be sold.
As we move into the second half of the year, investors will be keeping a close watch on their portfolios. There are plenty of financial gurus who are predicting the end of the bull market run, and there are plenty on the other side who believe that stocks are bound for greater heights. Whichever way the markets go, investors will need to watch which companies are hitting their marks on the earnings front. Investors may closely follow sell-side analyst estimates. It is important to remember that analyst projections are just that, projections. Following analyst expectations can provide a good glimpse into company actions, but strictly following what the analysts are saying may lead to difficulty in the future. Doing careful and extensive individual stock research may provide the investor with a more robust scope with which to successfully trade the market.
A highly common way to study stocks is through fundamental analysis. Investors examining the fundamentals may be analyzing the underlying factors that can affect the performance of a particular company. When focusing in on a specific company, investors will look at company management, financial information, business prospects, and industry competition. The goal of digging into the numbers is often times a way to calculate the current value of a company and try to gauge the value into the future. Zooming in on the vital statistics of a company can help provide a glimpse of the company’s overall health.
Research analysts are predicting that MacroGenics, Inc. (NASDAQ:MGNX) will report earnings of $-1.03 per share when the firm issues their next quarterly report. This is the consensus earnings per share number according to data from Zack’s Research.
Most recently MacroGenics, Inc. (NASDAQ:MGNX) posted quarterly earnings of $-1.14 which compared to the sell-side estimates of -1. The stock’s 12-month trailing earnings per share stands at $-4.19. Shares have moved $8.02 over the past month and more recently, $-7.17 over the past week heading into the earnings announcement. There are 7 analyst projections that were taken into consideration from respected brokerage firms.
MacroGenics, Inc. (NASDAQ:MGNX) closed the last session at $17.1 and sees an average of 192221.16 shares trade hands in each session. The 52-week low of the stock stands at $15.31 while the current level stands at 10.49% of the 52-week High-Low range. Looking further out we can see that the stock has moved -7.92% over the past 12 weeks and -16.34% year to date.
6 analysts rate MacroGenics, Inc. a Buy or Strong Buy, which is 85.71% of all the analyst ratings.
This article is informational purposes only and should not be considered a recommendation to buy or sell the stock.